Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab

Area of Science:

• Neurovirology
• Immunology
• Epidemiology

Background:

• Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease linked to JC virus (JCV), a common polyomavirus.
• JCV infection is widespread, typically occurring before age 20, with the virus remaining latent until reactivation, often in immunosuppressed individuals.
• Increased PML incidence is associated with the AIDS pandemic and natalizumab therapy, highlighting the role of impaired cellular immunity.

Purpose of the Study:

• To explore the factors contributing to the increased incidence of PML in HIV-infected individuals.
• To investigate the distinct predisposition to PML observed in natalizumab recipients.
• To understand the pathogenesis of JCV-associated PML in various immunosuppressed populations.

Main Methods:

• Review of epidemiological data on PML incidence in relation to HIV/AIDS and natalizumab use.
• Analysis of JCV latency, reactivation patterns, and viral shedding in peripheral lymphocytes.
• Comparison of PML risk in different immunosuppressive conditions.

Main Results:

• PML incidence dramatically increased with the AIDS pandemic.
• Natalizumab, an alpha4 integrin inhibitor, is associated with a distinct predisposition to PML.
• JCV reactivation and detection in lymphocytes are significantly more common in immunosuppressed populations.

Conclusions:

• Impaired cellular immunity is a critical factor in PML development.
• HIV infection and natalizumab therapy represent significant risk factors for PML.
• Further research into these populations is crucial for elucidating PML pathogenesis and developing preventive strategies.